

Engagement Report for Clinical Commissioning Policies

Unique Reference Number	A03X12
Policy Title	Teriparatide for the treatment of osteogenesis imperfecta (Adults)
Accountable Commissioner	Debbie Hart
Clinical Reference Group	Specialised Endocrinology
Which stakeholders were contacted to be involved in policy development?	Specialised Endocrinology CRG membership Specialised Endocrinology CRG registered stakeholders Brittle Bone Society
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	Representatives of relevant Royal College or Professional Societies were contacted for Stakeholder Testing as part of the CRG
Which stakeholders have actually been involved?	All of the key stakeholders listed above were invited to comment
Explain reason if there is any difference from previous question	Not applicable
Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?	None

FOR PUBLIC CONSULTATION ONLY

<p>How have the stakeholders been involved? What engagement methods have been used?</p>	<p>The draft policy was circulated to the full membership of the CRG and registered stakeholders for one week for their views, both to establish whether any amendments to the policy are required, and to understand from their perspective what the key questions to ask at consultation might be.</p> <p>Three comments were received from CRG-registered stakeholders. No comments were received from CRG members.</p> <p>Key response themes were as follows:</p> <ul style="list-style-type: none"> (1) Stakeholders requested clarification as to whether teriparatide will be commissioned or not (2) Stakeholders identified the proposed changes are not likely to result in any issues with regard to health inequalities (3) Stakeholders requested that teriparatide should only be used in treatment of osteogenesis imperfecta in the context of a clinical trial, monitored through a disease registry and that the use is restricted to a small number of centres using common protocols
<p>What has happened or changed as a result of their input?</p>	<p>Stakeholders were invited to comment. See Appendix for detailed stakeholder comments.</p> <p>No updates were made to the policy proposition as the policy has a clear commissioning position. PWG noted that it supports the use of teriparatide in clinical trials, however this is outside the scope of the policy. Views on the impact on equalities were welcomed.</p> <p>No updates were made to the evidence review.</p>
<p>How are stakeholders being kept informed of progress with policy development as a result of their input?</p>	<p>This engagement report, along with the updated policy proposition will be circulated as part of the public consultation. Stakeholders will be notified and invited to comment further.</p>
<p>What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?</p>	<p>Public consultation for a period of 30 days as supported by stakeholders.</p>